Company profile: Abeona Therapeutics
1.1 - Company Overview
Company description
- Provider of gene and cell therapy R&D for rare genetic diseases, including Sanfilippo syndrome types A and B; Recessive Dystrophic Epidermolysis Bullosa (pz-cel, EB-101); and preclinical gene therapies ABO-503 for X-Linked Retinoschisis, ABO-504 for Stargardt Disease, ABO-505 for Autosomal Dominant Optic Atrophy; plus UX111 for MPS IIIA in partnership with Ultragenyx Pharmaceutical Inc.
Products and services
- EB-101: Phase 3 autologous, gene-corrected cell therapy for Recessive Dystrophic Epidermolysis Bullosa, using corrected patient cells as the therapeutic modality
- Pz-cel (prademagene zamikeracel): Autologous engineered cell therapy for Recessive Dystrophic Epidermolysis Bullosa, using gene transfer to deliver COL7A1 genes into a patient’s skin cells
- UX111: Phase 1/2 gene therapy for Sanfilippo Syndrome Type A (MPS IIIA), partnered with Ultragenyx Pharmaceutical Inc to address the disorder with targeted genetic intervention
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Abeona Therapeutics
Antiva Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics targeting diseases caused by HPV infection, including ABI-2280, a topical prodrug designed to treat high-grade cervical intraepithelial neoplasias (HSIL, CIN 2,3) and high-risk HPV infections by blocking HPV replication and inducing apoptosis in infected cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antiva Biosciences company profile →
Castle Biosciences
HQ: United States
Website
- Description: Provider of molecular and genomic diagnostic tests for cancer, including DecisionDx-Melanoma for risk of recurrence, metastasis and sentinel lymph node positivity in cutaneous melanoma; DecisionDx-SCC for nodal or distant metastasis risk in SCC; TissueCypher to predict progression to esophageal cancer in Barrett’s esophagus; DecisionDx-UM for metastatic risk in uveal melanoma; and IDgenetix to guide personalized mental health medication selection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Castle Biosciences company profile →
Strata Oncology
HQ: United States
Website
- Description: Provider of precision oncology solutions, including Strata Select, a DNA/RNA-based molecular profiling test guiding immunotherapy and other treatment selection for advanced cancer; the Immunotherapy Response Score predicting benefit of anti-PD-1/PD-L1 monotherapy; and clinical trials such as Strata PATH and Strata Trial enabling biomarker-guided evaluation and access to approved and investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Strata Oncology company profile →
Vigene Biosciences
HQ: United States
Website
- Description: Provider of gene delivery technologies and cell and gene therapy CDMO solutions, offering research- and cGMP-grade AAV, lentivirus, and adenovirus products and custom services, including ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral, supporting therapy development and production to advance biomedical research and make gene therapy affordable.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vigene Biosciences company profile →
Locus Biosciences
HQ: United States
Website
- Description: Provider of CRISPR-engineered precision antibacterial therapies using bacteriophages. Portfolio includes LBP-EC01 for E. coli urinary tract infections; LBP-PA01 and LBP-SA01 targeting P. aeruginosa and S. aureus with Janssen; and LBP-KP01 for K. pneumoniae supported by CARB-X. Also offers robotic bacteriophage discovery and synthetic biology to engineer phage products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Locus Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Abeona Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Abeona Therapeutics
2.2 - Growth funds investing in similar companies to Abeona Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Abeona Therapeutics
4.2 - Public trading comparable groups for Abeona Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →